Olanzapine

Generic Name: Olanzapine

Brand Names: Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₀N_₄S

CAS Number: 132539-06-1

Unique Ingredient Identifier: N7U69T4SZR

Background: Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resemb...

Indication: Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.
...

Associated Conditions: Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode

Associated Therapies: -

Clinical Trials

Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: asenapine
Drug: olanzapine

First Posted Date: 2005-09-21

Last Posted Date: 2024-08-15

Lead Sponsor: Organon and Co

Target Recruit Count: 481

Registration Number: NCT00212836

Metabolic Effects of Antipsychotics in Children

Phase 4

Completed

Conditions: Aggression
Attention Deficit-Hyperactivity
Oppositional Defiant Disorder
Pervasive Development Disorders
Bipolar Disorder

Interventions: Drug: aripiprazole
Drug: olanzapine
Drug: risperidone

First Posted Date: 2005-09-20

Last Posted Date: 2018-06-15

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 144

Registration Number: NCT00205699

Locations: 🇺🇸
Washington University School of Medicine, Psychiatry Dept., Saint Louis, Missouri, United States

Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features

Phase 4

Completed

Conditions: Bipolar Disorder
Schizoaffective Disorder

Interventions: Drug: Olanzapine
Drug: Lithium
Drug: Chlorpromazine

First Posted Date: 2005-09-20

Last Posted Date: 2018-08-31

Lead Sponsor: Melbourne Health

Target Recruit Count: 83

Registration Number: NCT00202293

Locations: 🇦🇺
ORYGEN Youth Health, Parkville, Victoria, Australia

Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment

Phase 4

Completed

Conditions: Schizophrenia

First Posted Date: 2005-09-19

Last Posted Date: 2012-06-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 360

Registration Number: NCT00191555

Locations: 🇫🇷
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) , or speak with your personal physician, Villejuif, France

Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania

Phase 4

Completed

Conditions: Bipolar Disorder

First Posted Date: 2005-09-19

Last Posted Date: 2007-01-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 120

Registration Number: NCT00190892

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, St. Petersburg, Russian Federation

Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response

Phase 4

Completed

Conditions: Depression, Bipolar

First Posted Date: 2005-09-19

Last Posted Date: 2007-01-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 150

Registration Number: NCT00191399

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Santurce, Puerto Rico
🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hato Rey, Puerto Rico

A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme

Phase 4

Completed

Conditions: Weight Gain

First Posted Date: 2005-09-19

Last Posted Date: 2007-01-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 60

Registration Number: NCT00191828

Locations: 🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speack with your personal physician., Sesto Fiorentino, Florence, Italy

Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode

Phase 4

Completed

Conditions: Bipolar Disorder

First Posted Date: 2005-09-19

Last Posted Date: 2006-07-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 180

Registration Number: NCT00191997

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Zamora, Spain

Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder

Phase 4

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: olanzapine
Drug: risperidone

First Posted Date: 2005-09-19

Last Posted Date: 2010-05-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 130

Registration Number: NCT00190749

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States

Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine

Phase 3

Terminated

Conditions: Bipolar Disorder

Interventions: Drug: Olanzapine

First Posted Date: 2005-09-19

Last Posted Date: 2016-10-04

Lead Sponsor: University Hospitals Cleveland Medical Center

Target Recruit Count: 18

Registration Number: NCT00194064

Locations: 🇺🇸
University Hospitals of Cleveland, Cleveland, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy